Tag: BioNTech

A surprising development emerged in mid-November when pharmaceutical giant Pfizer divested 54.7% of its stake in BioNTech, triggering a significant ...

A seismic development has rocked BioNTech's stock valuation following the complete divestment of Pfizer's substantial shareholding. The long-standing pandemic partner ...

The German biotech firm BioNTech finds itself navigating turbulent waters following a significant divestment by its longtime collaborator. In a ...

After a prolonged period of disappointing its shareholders, the pioneering coronavirus vaccine developer is showing signs of a potential resurgence. ...

Investors are rallying behind BioNTech stock despite the company's recent quarterly loss, signaling a potential turnaround for the vaccine developer. ...

Today marks a critical juncture for BioNTech as the German biotech firm unveils its strategic roadmap in New York. Investors ...

BioNTech's equity performance is presenting a conundrum for market participants. The company continues to deliver impressive revenue figures and has ...

BioNTech presents investors with a complex financial picture marked by contradictory signals. The German biotech firm reported a substantial 22% ...

Investors in the Mainz-based biotechnology firm BioNTech received an unexpected financial update, as the company dramatically revised its annual revenue ...

Investor attention is firmly fixed on BioNTech today as the German biopharmaceutical company prepares to release quarterly results that could ...